 |
|
|
 |
The Short Arthritis Assessment Scale: A Brief Assessment Questionnaire for Rapid Evaluation of Arthritis Severity in Research and Clinical Practice
FREDERICK WOLFE, KALEB MICHAUD, KRISTJIAN KAHLER, and MOHAMED OMAR
ABSTRACT. Methods. Data and items from the Medical Outcomes Study Short Form 36 (SF-36), the Western Ontario McMaster Osteoarthritis Index (WOMAC©), and visual analog scales (VAS) for pain and patient global severity were studied in 16,519 patients with arthritis. The Short Arthritis Assessment Scale (SAS) was developed by performing multivariable analyses that involved individually adding/subtracting items in differing regression models. The candidate items and scales were then studied by Rasch analysis, and tested for effect size, sensitivity to change, and reliability. The resultant scale was validated using data from a recent OA clinical trial. Results. The VAS pain and VAS global severity scales and 2 items from the WOMAC in the VAS format, difficulty going down stairs and difficulty shopping, were found to be the best predictors of change in health status. The 4-item SAS was reliable (Cronbach's alpha = 0.87), demonstrated good test-retest reliability (Lin's concordance coefficient = 0.85), was unidimensional, and was strongly correlated with other important clinical measures, indicating good construct validity. Using data from a recent randomized clinical trial in OA, the SAS performed better than the WOMAC pain scale and the SF-36 physical component score in detecting change, and at least as well as the clinical trial VAS pain scale. Conclusion. The SAS is a 4-item arthritis severity questionnaire that can be easily administered in primary care for patients with OA, but is suitable for use across all arthritis illnesses. Scoring is simple, requiring only the addition of four 10-point scales, and interpretation is straightforward. The SAS may have a role in rapid assessment of the arthritis patient in primary care practice. (J Rheumatol 2004;31:2472-9) Key Indexing Terms:
OSTEOARTHRITIS
From the Arthritis Research Center Foundation, University of Kansas School of Medicine, Wichita, Kansas; and Novartis Pharmaceuticals Corp., East Hanover, NJ, USA. F. Wolfe, MD; K. Michaud, BS, MS, Arthritis Research Center Foundation; K. Kahler, RPh, MSc; M. Omar, RPh, PhD, Novartis Pharmaceuticals Corporation. Address reprint requests to Dr. F. Wolfe, National Data Bank for Rheumatic Diseases, Arthritis Research Center Foundation, 1035 N. Emporia, Suite 230, Wichita, KS 67214. E-mail: fwolfe@arthritis-research.org Submitted September 23, 2003; revision accepted June 8, 2004. |